INTROD UCTION
Drug-induced orthostatic hypot en sion (O H), a com mo n side effect of heterocyclic a nd mon oamine ox idase inhibitor (MAO I) a n tide pressan ts, is often e ncou nte red in clinica l practi ce (1,2). One st udy found th at seve re sym pto matic O H (repeated fainting or fall in g) occ urre d in 9% of pat ients on imi pra mi ne, I I % of patients on ph en elzin e, and 17% of patients on tranylcypromin e (3). The adve rse co nseq uen ces of drug-induced OH are evide n t, particul arly for th e elde rly whe re fa lls can result in broken hips. Newer ant idepressants suc h as se ro to ne rg ic reupt ak e inhibit ors do not ca use significa n t blood pressure cha nges. H owever, so me patients may need treatm ent with het erocyclics a nd MAOIs because of refr act ory depression or specificity of resp on se. For exa m ple, patients m ay be preferentiall y resp on sive to MAO Is for a ne rg ic bipolar d epressions (4) or at ypical d epression s (5) . Thus, for some patients it is important to treat side effec ts suc h as OH rath er th an to swi tc h to anoth er a nt ide pressa n t.
Drug-induced OH, however, is ofte n difficult to manage (6) . Conservative treatments su ch as patient ed uca tion, vascular s toc kings, increased salt and increased fluid int ak e a re usu all y insufficient. Fludrocortison e, a mi ne ra locorticoid volum e expa nde r, has been th e mo st co m mo nly used ph arm acologic agent for a n tide pressan t-ind uce d OH. Fludrocortison e is effec tive in treating OH, but carries sign ifican t side effects suc h as resting hyperten sion , hypokal emia and congestive heart fai lure as well as ot her possibl e co r ticos teroid effec ts. Dop a mi ne rgic antago- 12 nist s suc h as m et acl opramide have been exte ns ively used as a trea t me nt for OH in Parkinson s di sease a nd a u to no m ic neurop athi es, a nd have also been successful in th e treatm ent of MAOI-indu ced OH (7) . Lik e ot he r ph en othiazine dru gs, met acl opramide act s ce n t rally a nd also has pot entiall y signifi cant side effects including ex t ra pyramidal sym ptoms, hyp erprolactinemia a nd tardive dyskin esia . Domperidone (trad en am e: Motilium) is a peripheral dop amin e a ntagonist th at does not cross th e blood brain barri er, ha s no ce nt ra l dop amin ergic ac tivity, and th e refore is devoid of th es e risks (8) . Recently domperidon e has bee n successfully used in sm a ll clinical trials for OH secondary to Pa rk inson s diseas e, diab etic a u to no m ic neuropathy, ce n t ral neurological inju ry a nd d r ug-induced OH. T his a r ticle will review th e lit erature add ress ing domperidon e as a t reatm e nt of OH. O ur lit erature searc h reveal ed only nin e a r ticles focu sin g on domperid one a nd ort hostatic hypot en sion. Domperidon e is m ainly used as a n upper gas t ro in tes tina l mo ti lity age n t (9). Lik e m etoclopramid e, it has anti em etic a nd gas t ro p ro kine tic pr op erties. Dom pe ridone is gen erally well tol erat ed and has a low incid en ce of sid e effects, pred om ina n tly dry mouth (1.9 %) , headach e (1.2 %), a bdo m inal cra m ps « 1%), a nd diarrhea « 1%) ( 10) . Althou gh it has no ce nt ral effects it ca n rai se p rol acti n levels ( 10). It s usual dosage ran ge is 30 to 60 mg daily for upper gas troin tes tina l mot ility d isord ers.
Becau se of it s a n tie me tic prop erties, domp eridone was used to treat t he nau sea a nd e me sis associa te d with dopaminergic age n ts in th e t reat m en t of Pa rkinsons d isease. The dop amine agoni st a po mo rp hine a lso ca uses O H , likely m ed iat ed throu gh peripheral , rather th an ce n t ra l, dop aminergic mech an ism s ( I I ) . A doubleblind st udy (12) in 4 dru g-free pati ents with Parkinson s di sease found th e ac ute administration of domperidone (100 ug/kg 1M), but not sa line, pr event ed th e nausea , sed a tion, a nd art erial hypot ension seen aft er a pomo r phine inj ection (20 ug/kg 1M). Poll ack e t al. (13) also st ud ied both th e acu te a nd chro nic blood pr essu re effec ts of domperidon e in two se pa ra te st ud ies of patients with Parkinsonis m. In a sing le-blind st udy involvin g 10 pati ents, domperidon e ( 12 mg 1M) or placeb o was ad m iniste re d , followed by I m g of a po mo r phine. In th e placeb o co nd ition, a po morphine sign ifican tly lowered supine a nd e rect blood pr essures. Th e domperidone sig nifica n tly incr eased sup ine diastolic blood pr essure, erect systolic a nd d iast olic blood pr essure, and block ed th e hypot en sive effects of a po mo rp hine. T he second s t udy exa m ine d th e lon ger-t erm blood pr essure effects of domperidon e in 16 pati ents with idiopathic Parkinson s dis eas e ch ro n ica lly treat ed with a variet y of dop a mi ne rgic drugs. Five of th es e patients had occasional asym p tom a tic OH. Pati ents we re give n eit he r pla cebo or domperidone for on e week in a double blind cross-ove r design . In th ese patients domperidon e slightly, but significa n tly, rai sed sup ine systo lic blood pr essure a nd e rect sys tolic a nd di astolic blood pr essure ove r th e on e-week period.
These e ncouraging results were not suppo rte d in ot her s t ud ies wit h domperidon e a nd brom ocriptine. Agid e t a l. found th at domp e ridone (60 mg/day) block ed brom ocriptine-induced nau sea a nd vom iting a nd allowed for ra pid a ttain me nt of high th erapeutic dos es of bromocriptine ( 14) . There was, however, no protect ion agains t hypot ension in thi s placeb o-controlled st udy. All fou r pa tie nt s who had ort hos tatic hypot en sion (out of a tot al of 17 subjects) were in th e dom pe ridone group. Two furth er reports by th e sa m e gro up found th at larger doses of domperidon e (150 m g/day) had no effec t on blood pr essure nor th e occ u r re nce of ort hos ta tic hypot e nsion in 20 patients treat ed with high-dose brom ocriptine ( 15, 16) , a lt ho ug h th ese two rep orts se e m to co nsist of th e sa me patient sa m ple. This discre pan cy in results wit h bromocriptine a nd a po mo rp hine sugges ts th at br om ocriptine-in d uced postural hypot en sion involves ce n t ral m ech anisms rather th an periph e ral m echan isms.
Althou gh th ese st ud ies of domperidon e a nd dop amine ago nist s have shown mixed results on blood pr essure effects, clinical st ud ies of domperidone in treat ing OH hav e ge nera lly been favorabl e. One rep ort found th at d ompe ridone (60 mg/day) was effec tive for treating th e OH of3 hypert en sive pati ents with conc u r re n t OH from seve ra l e tiolog ies (17) . Mont astruc c t a l. (I8) looked a t domp e rid on c's effec ts in 8 patients with "severe sym p tom a tic or t hosta tic hypot en sion " of va rious e tiolog ies (3 patients had ce n t ra l neurological injury, 2 cases had idiopathic OH, a nd 3 pa tien ts had drug-induced OH du e to clomipramine or antimitotic m edi cation ). Aft er 5 days of treatment with domperidone OH improved a nd sym p to ms disappea red in all cases. Aft er 5.0 ± 1.4 months mean follow-up th e ort hos ta tic d rop was significan tly reduced from 53.1 ± 4 mmHg before treatment to 25.0 ± 9.5 m mHg afte r domperidone. Domperidone ha s a lso been effective in treating sym p tomatic OH in diabetic a u tonom ic neuropathy (19) . Lopes de Faria et a l. (20) st ud ied 9 patients with di ab etic a u to no m ic neurop athy a nd showed th at ora l domperid one 30 m g/day for 3 days significa n tly decreased th e ort hos ta tic drop in blood pr essure. Six of th ese patients maintained th eir im prove me n t a fte r a 6-mo n t h follow-up.
DISC USSIO T
Th e m ech anism of ac tion of domperidon e on blood pressure rem ains poorl y underst ood . Peripherall y ac ting d op amine may have vasod ilat ing and naturi eti c effects, and excessive dop amin e release up on sta nd ing has been d escribed in pat ient s with OH (2 1). M et oclopramide is hypothesized to inhibit th ese effec ts and incr ease plasma levels of aldost erone and free e pineph rine (22) . Domperidon e's peripheral dopamin ergic block ad e may have sim ila r effec ts . Domperidon e is a lso a spec ific a n tagon ist of D2 pr esynapti c dopamin e recept ors (23) . Si nce norepineph rin e release is inhibited by dopaminergic activity on D2 receptors, domperidon e 's effec t on O H may be m ediated through e nha nce me nt of peripheral noradren e rgic act ivity. Preliminary st ud ies, how ever, hav e not found significa n t incr eases in plasm a re nin activit y, ald ost erone, responsiven ess to a ng iote ns in II , nor urinary ca techo lam ines th at might explain th e postural blood pr essure cha nges followin g domperidon e (20) .
In su m m ary, this review indi cat es that domperidon e was effective in t he treatm ent of sym ptom a tic OH du e to varied ca uses including di ab etic neu ro pat hy, ce ntral neurological inju ry, Parkinsoni sm a nd so m e dru g-induced OH. Howeve r, t hese st ud ies a re limit ed by small sam ple sizes, ope n clinica l d esign s, a nd th e inclu sion of m u lt iple e tiologies for OH. one com pared domp eridon e to ot he r effec tive treatm ents for OH. The mechanism for domperidon e's act ion on blood pressu re is unknown , so domperidone may be effec tive on ly for ce rtain etiolog ies of OH . Only on e patient in th es e st ud ies had a n tide pressan t-ind uce d OH . H oweve r, he te rocyclic and MAOI a n tide p ress a n ts co nt in ue to be essen tia l tools in our psyc hopharmacologi c a r ma me n ta r iu m, d espit e th eir hypot en sive side effec ts . For some patients with antid epressant-induced OH, particul arly th ose who did not respond to antidepressa n ts th at do not have OH as a side effect, it will be clinica lly advantageous to treat th e OH rather than switc hing drugs. Becau se domperidon e is a we ll-tolerated m edi cation with few side effec ts, it will be worthwhile to det ermine in controlled s t ud ies wh ether it is a n effec tive treatm ent for antid epressant -induced O H in t hese pati ents. Sin ce OH ca n be sym pto matic or asy m p to ma tic, tra nsient or continuous, future clinical st ud ies shou ld ope ration aliz e th e defin iti on and measurement of OH in orde r to d et ermine th e clinical versu s statis tica l sign ifica nce of t rea t m e n ts.
